期刊
ANTIOXIDANTS
卷 10, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/antiox10020218
关键词
Alzheimer models; NADPH oxidase; oxidative stress; NOX2; NOX4; NADPH oxidase inhibitors
资金
- Consejo Nacional de Ciencia y Tecnologia [CB286653]
- SIPCOFAA-IPN [SIP 20200211]
- CONACYT [254600, 782]
Alzheimer's disease is a major human dementia characterized by memory loss associated with oxidative stress in brain cells. Overexpression of NADPH oxidase in AD leads to the production of large amounts of reactive oxygen species, damaging brain cells and vasculature, making it a potential therapeutic target for AD.
Alzheimer's disease (AD) is one of the main human dementias around the world which is constantly increasing every year due to several factors (age, genetics, environment, etc.) and there are no prevention or treatment options to cure it. AD is characterized by memory loss associated with oxidative stress (OS) in brain cells (neurons, astrocytes, microglia, etc.). OS can be produced by amyloid beta (A beta) protein aggregation and its interaction with metals, mitochondrial damage and alterations between antioxidants and oxidant enzymes such as nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. NADPH oxidase produces reactive oxygen species (ROS) and it is overexpressed in AD, producing large amounts of superoxide anions and hydrogen peroxide which damage brain cells and the vasculature. In addition, it has been reported that NADPH oxidase causes an imbalance of pH which could also influence in the amyloid beta (A beta) production. Therefore, NADPH oxidase had been proposed as a therapeutic target in AD. However, there are no drugs for AD treatment such as an NADPH oxidase inhibitor despite great efforts made to stabilize the ROS production using antioxidant molecules. So, in this work, we will focus our attention on NADPH oxidase (NOX2 and NOX4) in AD as well as in AD models and later discuss the use of NADPH oxidase inhibitor compounds in AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据